So far as we are aware there are no reports on the poliovirus immunity of immigrants in the United Kingdom. Our results show that the children of immigrants in the Glasgow area do not constitute a health hazard with regard to poliomyelitis. This contrasts with reports from several other countries that children of immigrants predominate among the few residual cases of poliomyelitis, presumably because their parents may be less aware of the importance of immunisation than parents indigenous to the recipient, developed country." The present poliovirus activity in the United Kingdom-12 cases so far during 197712-underlines the danger of complacency, which is becoming widespread owing to the dramatic reduction in the incidence of paralytic poliomyelitis since the introduction of polio vaccination programmes. This and the fact thit children commonly accompany their parents on intercontinental journeys increase the chance of non-immune travellers mixing with people from countries where poliomyelitis is still endemic; conversely, emigrants from such areas are flocking to countries of high industrial development.
Antibody surveys are a more reliable method of assessing immunity than either statistics of vaccine uptake or waiting for sporadic cases or outbreaks of paralytic poliomyelitis to signal a dangerous decline of immunity due to complacent undervaccination Summary and conclusions To assess whether phosphate depletion is an aetiological factor in osteomalacic dialysis osteodystrophy we undertook a prospective trial of phosphate-enriched dialysis fluid, in association with oral la-hydroxycholecalciferol, for this condition. Thirty patients started the trial; of the 27 who completed more than 6 months' treatment, 14 had iliac crest bone biopsies at the beginning and end of the treatment period. Side effects included pruritus, stiffness, and increase in corneal and vascular calcification. Only one patient showed histological improvement of osteomalacia, and eight deteriorated; in seven the osteitis fibrosa worsened. Myopathy showed some improvement in four patients, but became worse in four.
This treatment does not seem to have a place in the routine management ofnon-hypophosphataemic patients on dialysis.
Introduction
In Newcastle upon Tyne and several other centres an appreciable proportion of patients on regular haemodialysis develop an incapacitating type of bone disease characterised by bone pain and numerous fractures accompanied by proximal myopathy.' 2 Histological examination shows osteomalacia, with few active osteoblasts and little or no osteitis fibrosa. Serum concentrations of alkaline phosphatase and parathyroid hormone are often raised only slightly or not at all. This syndrome has failed to respond to treatment with calcium carbonate and phosphate binders,3 vitamin D2 or dihydrotachysterol,3 1a-hydroxycholecalciferol,4 5 or 1-25-dihydroxycholecalciferol,6 or the withdrawal of hepatic-enzyme-inducing drugs. A similar syndrome is sometimes seen in hypophosphataemic osteomalacia. 7 Some patients with hypophosphataemia and osteomalacia being treated with dialysis have responded to phosphate therapy,10 11 and it has been suggested that phosphate depletion may contribute to renal osteodystrophy.12 We carried out a prospective trial of phosphate-enriched dialysis fluid in 30 patients for 6-12 months to see whether we could treat or prevent osteomalacia by improving phosphate balance.
Patients and methods
Thirty patients were entered in the trial, 15 men and 15 women, aged between 18 and 60 (mean 41) years. All had been on regular haemodialysis for more than 6 months, using Meltec Multipoint 1 m2 dialysers and Lucas Mark II proportionating units, and dialysing 5-7 hours three times a week against a dialysate calcium of 1-6 mmol/l.
One patient received a renal transplant before completing the trial; 13 refused follow-up bone biopsy, or were considered unsuitable for this because of previous bleeding or anticoagulation treatment; two could not tolerate the treatment. The analysis refers to the 14 patients from whom full details were obtained.
No patient had had hypophosphataemia, either before or after dialysis, in the three months before the trial, though some had had it previously. Six patients had been taking aluminium hydroxide within six months of starting phosphate treatment; this had been withdrawn before the trial. At the beginning of the trial five patients were already taking 1 a-hydroxy vitamin D3 (1 o-OHDO); the remaining patients were given 1 x-OHD3 within 6 weeks of starting phosphate. The dose was adjusted to avoid hypercalcaemia and ranged from 1 The meaning of the slow radiological healing of fractures or Looser zones in three of the seven patients in whom they were present is uncertain, as partially mineralised osteoid, which is radio-opaque, may appear around the fractures without there being any true remodelling and healing of trabecular bone. There was no improvement in histological osteomalacia in these cases.
Histologically, osteomalacia became worse in eight patients, three of whom showed an appreciable increase in osteitis fibrosa, and improved in only one. There is thus no evidence that phosphate treatment-or induction of osteitis fibrosa-promotes healing of osteomalacia.
The effect of phosphate treatment on myopathy and on bone pain, which was present in those with severe myopathy, is more difficult to assess. Assessment of myopathy is affected by the patient's motivation, which may have a large role in patients selected for special treatment. Nevertheless, two patients showed unequivocal improvement of myopathy, though not of bone histology; one was wheelchair-bound at the start of therapy through weakness and pain, was walking within three months, and is now clinically normal. Three months after starting treatment repeat endoscopy showed complete healing of the ulcer. Widespread punctate erosive gastritis was noted, however, with altered blood at some erosion sites; there was also a florid duodenitis, with several areas of punctate erosion. Three months later endoscopy showed an almost identical appearance. On each occasion the patient had no symptoms and said that he had taken neither aspirin nor alcohol. Blood urea and electrolyte concentrations, liver function values, and routine haematological tests assessed at monthly intervals remained normal throughout. At six months a blood sample taken six hours before endoscopy showed no trace of either salicylate or alcohol. Four months after stopping treatment the patient was still asymptomatic and endoscopy showed no evidence of erosive gastritis, although duodenitis was still present. A pentagastrin test showed a basal acid output of 10-8 mmol(mEq)/h and a stimulated acid output of 58-9 mmol(mEq)/h.
Comment
These endoscopy appearances usually occur in patients who have recently taken either aspirin or alcohol or both. We were satisfied that our patient had taken neither. During our study over 40 endoscopic examinations were carried out on patients receiving continuous
